XBIO

Xenetic Biosciences, Inc. NASDAQ Listed Jun 30, 2016

Healthcare ·Biotechnology ·US · xeneticbio.com

$3.12

Mkt Cap $5.3M

52w Low $1.90 10.1% of range 52w High $13.93

50d MA $2.93 200d MA $2.94

P/E (TTM) -1.9x

EV/EBITDA 1.5x

P/B 0.7x

Debt/Equity 0.0x

ROE -36.2%

P/FCF -1.6x

RSI (14) —

ATR (14) —

Beta 2.21

50d MA $2.93

200d MA $2.94

Avg Volume 22.1K

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

SIC Code

2834

CIK (SEC)

1534525

Phone

781 778 7720

40 Speen Street · Framingham, MA 01701 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 12, 2026	AMC	-0.52	-0.22	+57.7%	2.57	+12.5%	+9.3%	+20.3%	-7.7%	+0.0%	-2.9%	—
Nov 12, 2025	AMC	-0.49	-0.33	+32.7%	2.64	-1.1%	-2.7%	+1.2%	-4.2%	+3.2%	-1.2%	—
Aug 12, 2025	AMC	-0.64	-0.45	+29.7%	2.79	-0.7%	+7.2%	-2.0%	-2.4%	+2.8%	-4.1%	—
May 13, 2025	AMC	-0.72	-0.59	+18.1%	3.06	+4.6%	+2.0%	-3.5%	-3.3%	+0.0%	+4.5%	—
Nov 12, 2024	AMC	-0.14	-0.28	-100.0%	4.13	-2.9%	-11.6%	+0.3%	+0.8%	+6.8%	-1.0%	—
Aug 13, 2024	AMC	-0.83	-0.83	+0.0%	3.50	-14.0%	-6.0%	-4.3%	+3.5%	+15.3%	+8.2%	—
May 9, 2024	AMC	-0.79	-0.78	+1.3%	4.04	-1.0%	-3.5%	+0.5%	-3.1%	+4.2%	-10.4%	—
Mar 21, 2024	AMC	-0.87	-0.77	+11.5%	3.95	-7.6%	-2.3%	+2.3%	-3.3%	+4.2%	-5.3%	—
Nov 10, 2023	AMC	-1.12	-0.69	+38.4%	2.91	-1.0%	-0.3%	+8.6%	-1.6%	-1.6%	+4.9%	—
Aug 11, 2023	AMC	-1.13	-0.69	+38.9%	3.64	+2.2%	+0.3%	+1.1%	+2.7%	+0.8%	-6.8%	—
May 11, 2023	AMC	-1.10	-0.60	+45.5%	4.00	+2.5%	-17.5%	+0.3%	-11.5%	-1.7%	-7.6%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 9	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$2.30	$2.31	+0.4%	+5.2%	-1.7%	-3.4%	+4.8%	+2.9%
Mar 20	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$3.52	$3.45	-2.0%	-3.4%	-0.9%	+0.3%	+0.0%	-3.3%
Dec 5	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$4.53	$4.40	-2.9%	-0.4%	-1.1%	-2.9%	+0.5%	-2.5%
May 16	HC Wainwright & Co.	Downgrade	Buy → Neutral	—	$3.31	$3.20	-3.3%	-11.5%	-1.7%	-7.6%	+4.5%	+1.8%
Apr 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.44	$4.30	-3.2%	+4.3%	-0.6%	+9.8%	-5.9%	+0.4%
May 2	HC Wainwright & Co.	Maintains	Buy → Buy	—	$7.44	$7.50	+0.8%	-0.9%	+0.4%	+4.6%	-3.1%	-2.7%
Jan 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$24.20	$26.60	+9.9%	+11.0%	-4.3%	+4.3%	+7.5%	-5.6%
Nov 25	Ladenburg Thalmann	Maintains	Buy → Buy	—	$9.70	$10.20	+5.2%	+0.0%	+4.1%	+12.9%	-2.6%	+4.5%
Dec 20	Ladenburg Thalmann	Maintains	Buy → Buy	—	$419.76	$438.00	+4.3%	+1.9%	-0.3%	+0.1%	+2.5%	+0.0%

Data updated apr 27, 2026 10:23am · Source: massive.com